CureVac N.V. (CVAC) deserves deeper analysis

While CureVac N.V. has underperformed by -2.89%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CVAC fell by -64.72%, with highs and lows ranging from $12.48 to $3.41, whereas the simple moving average fell by -50.59% in the last 200 days.

On June 08, 2023, SVB Securities started tracking CureVac N.V. (NASDAQ: CVAC) recommending Outperform.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Analysis of CureVac N.V. (CVAC)

Further, the quarter-over-quarter increase in sales is 58.86%, showing a positive trend in the upcoming months.

To gain a thorough understanding of CureVac N.V.’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -51.09% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.41, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.

It is also very valuable to look at average volume as an indicator of volatility for a stock, and CVAC is recording an average volume of 1.07M. Furthermore, long-term investors anticipate a median target price of $13.37, showing growth from the present price of $3.69, which can serve as yet another indication of whether CVAC is worth investing in or should be passed over.

How Do You Analyze CureVac N.V. Shares?

The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 59.08%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 15.28% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.

Are institutional investors increasing their holdings in CVAC shares?

The recent increase in stakes in CVAC appears to be a result of several institutional investors and hedge funds increasing their positions. RA Capital Management LP’s position in CVAC has decreased by -13.41% in the first quarter. The company now owns 10,604,344 shares of the stock, with a value of $44.64 million, following the sale of -1,641,611 additional shares during the last quarter. T. Rowe Price Associates, Inc. made another decreased to its shares in CVAC during the first quarter, downing its stake by -10.56%. During the last quarter, the company dropped down -376,327 additional shares for a total stake of worth $13.42 million, bringing number of shares owned by the company to 3,187,699.

During the first quarter, Avidity Partners Management LP subtracted a -1,183,900 position in CVAC. Citadel Advisors LLC purchased an additional 0.72 million shares in the last quarter, increasing its holdings by 30.60%, now holding 3.07 million shares worth $12.94 million. At the end of the first quarter, Millennium Management LLC decreased its CVAC holdings by -4.01% and now holds 1.81 million CVAC shares valued at $7.61 million with the lessened 75578.0 shares during the period. CVAC shares are owned by institutional investors to the tune of 15.28% at present.

Related Posts